New and future drug development for gastroesophageal reflux disease

Journal of Neurogastroenterology and Motility

Volumn 20, Issue 1, 2014, Pages 6-16

  Maradey Romero, Carla ^a   Fass, Ronnie ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors

Indexed keywords

AGN 201904Z; ALEVIUM; BENATOPRAZOLE; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ; ESOMEPRAZOLE; GASTROINTESTINAL AGENT; ILAPRAZOLE; LAFUTIDINE; LANSOPRAZOLE; LAVOLTIDINE; LINAPRAZAN; NIZATIDINE; NMI 826; OX 17; POTASSIUM COMPETITIVE ACID BLOCKER; PROTON PUMP INHIBITOR; REVAPRAZAN; SECRETOL; SORAPRAZAN; TAK 438; UNCLASSIFIED DRUG; VECAM;

ESOPHAGUS PAIN; GASTROESOPHAGEAL REFLUX; HUMAN; LOWER ESOPHAGUS SPHINCTER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STOMACH PAIN;

EID: 84891669630     PISSN: 20930879     EISSN: 20930887     Source Type: Journal    
DOI: 10.5056/jnm.2014.20.1.6     Document Type: Review

References (96)

1. Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006;101:1900-1920.
2. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-717.
3. El-Serag HB, Sweet S, Winchester CC, Dent J. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut Published Online First: 13 Jul 2013. gutjnl-2012-304269
4. Peery AF, Dellon ES, Lund J, et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 2012;143:1179-1187.
5. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd.Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112:1448-1456.
6. Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease:a meta-analysis. Gastroenterology 1997;112:1798-1810.
7. Hershcovici T, Fass R. Nonerosive reflux disease (NERD)-an update. J Neurogastroenterol Motil 2010;16:8-21.
8. Hershcovici T, Fass R. Gastro-oesophageal reflux disease beyond proton pump inhibitor therapy. Drugs 2011;71:2381-2389.
9. Fass R. Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment. Clin Gastroenterol Hepatol 2012;10:338-345.
10. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.
11. Fass R. Proton Pump Inhibitor Failure - what are the therapeutic options?Am J Gastroenterol 2009;104(suppl 2):S33-S38.
12. Fass R, Shapiro M, Dekel R, Sewell J. Systematic Review: proton-pump inhibitor failure in gastro-oesophageal reflux disease-where next? Aliment Pharmacol Ther 2005;22:79-94.
13. Moore JM, Vaezi MF. Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined? Curr Opin Gastroenterol 2010;26:389-394.
14. Fass R, Hixson LJ, Ciccolo ML, Gordon P, Hunter G, Rappaport W. Contemporary medical therapy for gastroesophageal reflux disease. Am Fam Physician 1997;55:205-212, 217-218.
15. Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenalulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. Gastroenterology 2000;118(2 suppl1):S9-S31.
16. Wang WH, Huang JQ, Zheng GF, et al. Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis. World J Gastroenterol 2005;11:4067-4077.
17. Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as inicitial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965-973.
18. Fujiwara Y, Higuchi K, Nebiki H, et al. Famotidine vs. omeprazole:a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-esophageal reflux disease. Aliment Pharmacol Ther 2005;21(suppl 2):10-18.
19. Pappa KA, Gooch WM, Buaron K, et al. Low-dose ranitidine for the relief of heartburn. Aliment Pharmacol Ther 1999;13:459-465.
20. Pappa KA, Williams BO, Payne JE, Buaron KS, Mussari KL, Ciociola AA. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther 1999;13:467-473.
21. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-1339.
22. Iwakiri K, Kawami N, Sano H, et al. The effects of nizatidine on transient lower esophageal sphincter relaxations (TLESRs) and acid reflux in healthy subjects. J Smooth Muscle Res 2011;47:157-166.
23. Ohara S, Haruma K, Kinoshita Y, Kusano M. A double-blind, controlled study comparing lafutidine with placebo and famotidine in Japanese patients with mild reflux esophagitis. J Gastroenterol 2010;45:1219-1227.
24. Inamori M, Iida H, Hosono K, et al. The histamine H2 receptor antagonist lafutidine in Japanese patients with non-erosive reflux disease. Hepatogastroenterology 2010;57:1430-1434.
25. Dewan B, Philipose N. Lafutidine 10 mg versus rabeprazole 20 mg in the treatment of patients with heartburn-dominant uninvestigated dyspepsia: a randomized, multicentric trial. Gastroenterol Res Pract 2011;2011:640685.
26. Gatehouse D, Wedd DJ, Paes D, et al. Investigations into the genotoxic potential of loxtidine, a long-acting H2 receptor antagonist. Mutagenesis 1998;3:57-58.
27. NCT00405119. A study to investigate the effectiveness of AH234844 (Lavoltidine) compared with nexium and ranitidine. Available from URL: http://clinicaltrials.gov/show/NCT00405119 (accessed November 2013).
28. NCT00551473. Open-label comparison of 24hr gastric pH on Days 1, 2, 7 with once-daily administration of Lavoltidine 40 mg. Available from URL: http://clinicaltrials.gov/show/NCT00551473 (accessed November 2013).
29. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology 2002;122:625-632.
30. Scarpignato C. New drugs to suppress acid secretion: current and future developments. Drug Discov Today Ther Strateg 2007;4:155-163.
31. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266-280.
32. Howden CW. Appropriate acid suppression in the treatment of acid-related conditions. Pharmacol Ther 1994;63:123-134.
33. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev 2007;(2):CD003244.
34. Dean BB, Gano AD Jr, Knight K, Ofman JJ, Fass R. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-664.
35. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-1240.
36. Hershcovici T, Jha LK, Fass R. Dexlansoprazole MR: a review. Ann Med 2011;43:366-374.
37. Lee RD, Vakily M, Mulford D, Wu J, Atkinson SN. Clinical trial:the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor - evidence for dosing flexibility. Aliment Pharmacol Ther 2009;29:824-833.
38. Sharma P, Shaheen NJ, Perez MC, et al. Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies. Aliment Pharmacol Ther 2009;29:731-741.
39. Fass R, Chey WD, Zakko SF, et al. Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2009;29:1261-1272.
40. Fass R, Johnson DA, Orr WC, et al. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD. Am J Gastroenterol 2011;106:421-431.
41. Fass R, Inadomi J, Han C, Mody R, O'Neil J, Perez MC.Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release. Clin Gastroenterol Hepatol 2012;10:247-253.
42. Galmiche JP, Bruley Des Varannes S, Ducrotté P, et al. Tenatoprazole,a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy subjects. Aliment Pharmacol Ther 2004;19:655-662.
43. Thomson AB, Cohen P, Ficheux H, et al. Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers:a randomized three-way crossover study. Aliment Pharmacol Ther 2006;23:1179-1187.
44. Hunt RH, Armstrong D, Yaghoobi M, James C. The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects. Aliment Pharmacol Ther 2010;31:648-657.
45. Sachs G, Shin JM, Hunt R. Novel approaches to inhibition of gastric acid secretion. Curr Gastroenterol Rep 2010;12:437-447.
46. Hunt RH, Armstrong D, Yaghoobi M, et al. Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z. Aliment Pharmacol Ther 2008;28:187-199.
47. Wang L, Zhou L, Hu H, Lin S, Xia J. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blind and controlled phase III trial. Curr Med Res Opin 2012;28:101-109.
48. Wang L, Zhou L, Lin S, Hu H, Xia J. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastroenterol 2011;45:322-329.
49. DU YQ, Guo WY, Zou DW, et al. Acid inhibition effect of ilaprazole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis 2012;13:113-119.
50. NCT00471094. Safety and Efficacy of Ilaprazole 5, 20 and 40 mg QD and Lansoprazole 30 mg QD on Healing of Erosive Esophagitis (NCT00471094). Available from URL: http://www.clinicaltrials.gov/show/NCT00471094 (accessed November 2013).
51. Hanmi Pharmaceutical Co., Ltd. Hamni press center, latest news.Available from URL: http://www.hanmipharm.com/meng/news/latest_view.asp?seq=281_id=7 (accessed November 2013).
52. U.S Food and Drug Administration (FDA). FDA/Center for Drug Evaluation and Research Office of Communications,Division of Online Communications. Available from URL: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search. Drug Details (accessed November 2013).
53. Chowers Y, Atarot T, Kostadinov A, et al. PPI activity is optimized by VB101, a parietal cell activator. Gastroenterology 2008;134(suppl):A172.
54. Chowers Y, Atarot T, Pratha VS, Fass R. The effect of once daily omeprazole and succinic acid (VECAM) vs once daily omeprazole on 24-h intragastric pH. Neurogastroenterol Motil 2012;24:426-431, e208-e209.
55. Orexo announces results confirming the clinical profile of OX17 in reflux disease (GERD). Available from URL: http://www.orexo.com/en/Investor-Relations/Press-releases/?guid=341021 (accessed November2013).
56. Dutta U, Armstrong D. Novel pharmaceutical approaches to reflux disease. Gastroenterol Clin North Am 2013;42:93-117.
57. Sorba G, Galli U, Cena C, et al. A new furoxan NO-donor rabeprazole derivative and related compounds. Chembiochem 2003;4:899-903.
58. Andersson K, Carlsson E. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases. Pharmacol Ther 2005;108:294-307.
59. Kahrilas PJ, Dent J, Lauritsen K, et al. A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis. Clin Gastroenterol Hepatol 2007;5:1385-1391.
60. Dent J, Kahrilas PJ, Hatlebakk J, et al. A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease. Am J Gastroenterol 2008;103:20-26.
61. Simon WA, Herrmann M, Klein T, et al. Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther 2007;321:866-874.
62. Choi HY, Noh YH, Jin SJ, et al. Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers. Clin Ther 2012;34:1999-2010.
63. Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals. J Pharmacol Exp Ther 2011;337:797-804.
64. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem 2012;55:4446-4456.
65. Hershcovici T, Mashimo H, Fass R. The lower esophageal sphincter. Neurogastroenterol Motil 2011;23:819-830.
66. Rohof WO, Aronica E, Beaumont H, Troost D, Boeckxystaens GE.Localization of mGluR5, GABAB, GABAA, and cannabinoid receptors on the vago-vagal reflex pathway responsible for transient lower esophageal sphincter relaxation in humans: an immunohistochemical study. Neurogastroenterol Motil 2012;24:383, e173.
67. Lehmann A, Blackshaw LA, Brändén L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002;123:1129-1134.
68. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G. Effect of delta9-tetrahydrocannabinol, a cannabinoid receptor agonist, on the triggering of transient lower oesophageal sphincter relaxations in dogs and humans. Br J Pharmacol 2009;156:153-162.
69. Scarpellini E, Blondeau K, Boecxstaens V, et al. Effect of rimonabant on oesophageal motor function in man. Aliment Pharmacol Ther 2011;33:730-737.
70. Lehmann F, Hildebrand P, Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 2003;63:1785-1797.
71. Clavé P, González A, Moreno A, et al. Endogenous cholecystokinin enhances postprandial gastroesophageal reflux in humans through extrasphincteric receptors. Gastroenterology 1998;115:597-604.
72. Zerbib F, Bruley Des Varannes S, Scarpignato C, et al. Endogenous cholecystokinin in postprandial lower esophageal sphincter function and fundic tone in humans. Am J Physiol 1998;275(6 Pt 1):G1266-G1273.
73. Beglinger C, Degen L, Schroller S, D'Amato M, Persiani S. Oral itriglumide, a specific CCK2/gastrin receptor antagonist, inhibits gastrin stimulated gastric acid secretion in humans. Gut 2004;54(suppl VII):A36.
74. Hershcovici T, Fass R. Transient lower esophageal sphincter relaxation reducers - have we hit a brick wall? Aliment Pharmacol Ther 2011;33:1256-1257.
75. Lal R, Sukbuntherng J, Tai EH, et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism,and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009;330:911-921.
76. Vakil NB, Huff FJ, Bian A, Jones DS, Stamler D. Arbaclofen Placarbil in GERD: a randomized, double-blind, placebo-controlled study. Am J Gastroenterol 2011;106:1427-1438.
77. Boeckxstaens GE, Beaumont H, Mertens V, et al. Effects of lesogaberan on reflux and lower esophageal sphincter function in patients with gastroesophageal reflux disease. Gastroenterology 2010;139:409-417.
78. Boeckxstaens GE, Beaumont H, Hatlebakk J, Silberg D, Adler J, Denison H. Efficacy and tolerability of the novel reflux inhibitor, AZD3355, as add-on treatment in GERD patients with symptoms despite proton pump inhibitor therapy. Gastroenterology 2009;136(suppl1):A436.
79. Zerbib F, Bruley des Varannes S, Roman S, et al. Randomised clinical trial: effects of monotherapy with ADX10059, a mGluR5 inhibitor,on symptoms and reflux events in patients with gastrooesophageal reflux disease. Aliment Pharmacol Ther 2011;33:911-921.
80. Rohof WO, Lei A, Hirsch DP, et al. The effects of a novel metabotropic glutamate receptor 5 antagonist (AZD2066) on transient lower oesophageal sphincter relaxations and reflux episodes in healthy volunteers. Aliment Pharmacol Ther 2012;35:1231-1242.
81. Ruth M, Hamelin B, Röhss K, Lundell L. The effect of mosapride,a novel prokinetic, on acid reflux variables in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1998;12:35-40.
82. Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol 2010;45:413-421.
83. Kim YS, Kim TH, Choi CS, et al. Effect of itopride, a new prokinetic in patients with mild GERD: a pilot study. World J Gastroenterol 2005;11:4210-4214.
84. Rohof WO, Bennink RJ, de Ruigh AA, Hirsch DP, Zwinderman AH, Boeckxstaens GE. Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period. Gut 2012;61:1670-1677.
85. Mertens V, Blondeau K, Pauwels A, et al. Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients. Dig Dis Sci 2009;54:972-979.
86. Frampton JE. Prucalopride. Drugs 2009;69:2463-2476.
87. Choung RS, Ferguson DD, Murray JA, et al. A novel partial 5HT3 agonist DDP733 after a standard refluxogenic meal reduces reflux events: a randomized, double-blind, placebo-controlled pharmacodynamic study. Aliment Pharmacol Ther 2008;27:404-411.
88. Krarup AL, Ny L, Astrand M, et al. Randomised clinical trial: the efficacy of a transient receptor potential vanilloid 1 antagonist AZD1386 in human oesophageal pain. Aliment Pharmacol Ther 2011;22:1113-1122.
89. Fass R. Functional heartburn: what it is and how to treat it. Gastrointest Endosc Clin N Am 2009;19:23-33.
90. Hershcovici T, Achem SR, Jha LK, Fass R. Systematic review: the treatment of noncardiac chest pain. Aliment Pharmacol Ther 2012;35:5-14.
91. Fass R, Dickman R. Non-cardiac chest pain: an update. Neurogastroenterol Motil 2006;18:408-417.
92. Kort ME, Kym PR. TRPV1 antagonists: clinical setbacks and prospects for future development. Prog Med Chem 2012;51:57-70.
93. Gunthorpe MJ, Chizh BA. Clinical development of TRPV1 antagonists:targeting a pivotal point in the pain pathway. Drug Discov Today 2009;14:56-67.
94. Adachi K, Furuta K, Miwa H, et al. A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory noneroxive reflux disease. Dig Dis Sci 2012;57:1609-1617.
95. Araki H, Kato T, Onogi F, et al. Combination of proton pump inhibitor and rebamipide, a free radical scavenger, promotes artificialulcer healing after endoscopic submucosal dissection with dissection size > 40 mm. J Clin Biochem Nutr 2012;51:185-188.
96. Kawahara Y, Nakase Y, Isomoto Y, et al. Role of macrophage colony-stimulating factor (M-CSF)-dependent macrophages in gastriculcer healing in mice. J Physiol Pharmacol 2011;62:441-448.